Objective: To explore the therapeutic effect of camrelizumab combined with chemotherapy in patients with advanced lung adenocarcinoma. Methods: This study was a double-blind controlled, prospective randomized clinical intervention trial. A total of 100 patients with advanced lung adenocarcinoma received in Suzhou Municipal Hospital from January 2020 to January 2021 were selected, and they were divided into an observation group (50 cases) and a control group (50 cases) by random number table method. The control group was treated with chemotherapy, and the observation group was treated with camrelizumab on the basis of the control group. The therapeutic efficacy, peripheral blood indexes, adverse reactions, and Karnofsky Performance Status (KPS)/Brief Fatigue Inventory (BFI) scores were compared between the 2 groups. Results: The disease control rate (DCR) in the observation group was 88.00%, which was higher than 68.00% in the control group, and the difference was statistically significant (P<0.05). After the treatment, the concentration of human cytokeratin 21-1 fragment (Cyfra21-1), carcinoembryonic antigen (CEA) serum concentration, and BFI score in the observation group were lower than those in the control group, the KPS score was higher than that in the control group, and the differences were statistically significant (all P<0.05). There was no significant difference in carbohydrate antigen 199 (CA199), the incidence of adverse reactions, and survival rate within 10 months between the 2 groups after the treatment (all P>0.05). Conclusion: Advanced lung adenocarcinoma treated with camrelizumab combined with chemotherapy can effectively delay the development of the disease and improve the quality of life of patients. However, compared with chemotherapy alone, it does not have much impact on the short-term survival of patients.